Drugs / Untreated CB
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01627314 Comparator | Jul 2012 → Mar 2016 | hematopoietic and lymphoid system neoplasm | Fate Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Untreated CB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01627314 ↗ |
| Modality | Cell therapy | “they will receive 2 Human Leukocyte Antigen (HLA)-matched or partially matched umbilical cord blood (UCB) units” NCT01627314 ↗ |